My approach to and thoughts on the typing of ovarian carcinomas

Journal of Clinical Pathology

Volumn 61, Issue 2, 2008, Pages 152-163

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIOID CARCINOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL INFORMATION; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; OVARY MIXED CARCINOMA; OVARY MUCINOUS ADENOCARCINOMA; OVARY SEROUS ADENOCARCINOMA; OVARY SQUAMOUS CARCINOMA; OVARY TRANSITIONAL CARCINOMA; OVARY UNDIFFERENTIATED CARCINOMA; PRIORITY JOURNAL; REPRODUCIBILITY; THINKING; ADENOCARCINOMA; CLASSIFICATION; COLLOID CARCINOMA; CYSTADENOCARCINOMA; FEMALE; OVARY TUMOR; PATHOLOGY; REVIEW; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CARCINOMA, TRANSITIONAL CELL; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 38849097832     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.049478     Document Type: Article

References (89)

1. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
2. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.
3. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
4. Koonings PP, Campbell K, Mishell DR Jr, et al. Relative freguency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989;74:921-6.
5. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004:23:41-4.
6. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
7. Lee KR, Young RH. The distinction between primary and secondary mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003;27:281-92.
8. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovary: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27;985-93.
9. Lewis MR, Deavers MT, Silva EG, et al. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol 2006;30;177-84.
10. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005:47:231-47.
11. Berezowski K, Stasny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996;9:1040-4.
12. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colon and breast origin. Comparison between a statistical and intuitive approach. J Clin Pathol 1999;52:283-90.
13. Park SO, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-85.
14. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to 'pseudomyxoma peritonei'. Am J Surg Pathol 1995;19:1390-408.
15. Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol 1995;8:573-6.
16. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997;16:1-9.
17. Hart WR. Mucinous tumors of the ovary: a review: Int J Gynecol Pathol 2005;24:4-25.
18. Brugghe J, Baak JP, Wiltshaw E, et al. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. Int J Gynecol Cancer 1995;5:262-8.
19. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993;3:72-9.
20. Baak JP, Langley FA, Talerman A, et al. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986;8:354-7.
21. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med 1987;111:819-29.
22. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS 1991;99:353-8.
23. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1996;54:54-8.
24. Han G, Gilks CB, Leung S, et al. Interobserver variation in the diagnosis of ovarian clear cell carcinoma and mixed ovarian epithelial carcinomas with a clear cell component. Lab Invest 2007:200A.
25. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002;55:27-31.
26. Sato Y, Shimamoto T, Amada S, et al. Prognostic value of histologic grading of ovarian carcinomas. Int J Gynecol Pathol 2003;22:52-6.
27. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol 1998;70:2-12.
28. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
29. Cho EY, Choi Y, Chae SW, et al. Immunohistochemical expression of the study of adhesion molecules in ovarian serous neoplasms. Pathol Int 2006;56:62-70.
30. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004;23:97-9.
31. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63.
32. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109-15.
33. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
34. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-9.
35. Vang R. Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 2007;31;653-63.
36. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23:200-5.
37. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-9.
38. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
39. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003;22:37-41.
40. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-24.
41. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8.
42. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutation are restricted to low-grade serous tumours. J Pathol 2004;202:336-40.
43. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;32:87-95.
44. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
45. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
46. Lee Y, Medeiros F, Mindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006;13:1-7.
47. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2007;30:230-6.
48. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496- 504.
49. Malpica A, Deavers MT, Tornos C, et al. Interobserver variability of the two-tier system for grading ovarian serous carcinoma. Mod Pathol 2005;18:194A.
50. Weir MM, Bell DA, Young RH. Grade 1 peritoneal carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. Am J Surg Pathol 1998;22:849-62.
51. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1. bcl2, her-2/neu and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005;29:1034-41.
52. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic análisis. Am J Surg Pathol 2007;31:1007- 12.
53. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenculature, diagnostic criteria, and behaviour. Hum Pathol 2004;35:959-60.
54. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004;28:1311-8.
55. Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol 2003;22:42-51.
56. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal and pancreaticobiliary epithelial cells. Cancer 1992;69:2131-42.
57. Vang R, Gow AM, Wu LS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19:1421-8.
58. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006;30:1130-9.
59. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006;25:83-9.
60. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105.
61. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007;31:854-69.
62. Scott M, McCluggage WG. Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol 2006;21:81-92.
63. Cantrecasas M, Villaneuva A, Matias-Guiu X, et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997;70:1581-6.
64. Takeshima Y, Amatya VJ, Dalmaru Y, et al. Heterogenous genetic alteration in ovarian mucinous tumors: application and usefulness of laser capture microdissection. Hum Pathol 2001;32:1203-8.
65. Gemignani ML, Schlaerth AC, Bogomolnly F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378-81.
66. Sainz DIC, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996;60:238-44.
67. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001;20:133-9.
68. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000;24:1465-9.
69. Tornos C, Silva EG, Ordonez NG, et al. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. Am J Surg Pathol 1995;19:1343-53.
70. Roth LM, Liban E, Czernobilsky B. Ovarian endometrioid tumors mimicking Sertoli and Sertoli-Leydig cell tumors. Sertoliform variant of endometrioid carcinoma. Cancer 1982;50:1322-31.
71. Young RH, Prat J, Scully RE. Ovarian endometrioid carcinomas resembling sex-cord stromal tumors. A clinicopathologic analysis of 13 cases. Am J Surg Pathol 1982;6:513-22.
72. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005;29:157-66.
73. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol 2005;29:281-94.
74. Lerwill MF, Young RH. Ovarian metastasis of intestinal-type gastric carcinoma: a clinicopathologic study of 4 cases with contrasting features to those of Krukenberg tumor. Am J Surg Pathol 2006;30:1382-8.
75. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005;22:3-32.
76. Fragetta F, Pelosi G, Cafici A, et al. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch 2003;443:782-6.
77. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005;18:19-25.
78. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol 2004;12:127-31.
79. Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary; similar frequency of β-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004;35:1360-8.
80. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9.
81. Tan DS, Kaye S. Ovarian clear cell carcinoma: a continuing enigma. J Clin Pathol 2007;60:355-60.
82. Cameron RI, Ashe P, O'Rourke DM, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 2003;22:272-6.
83. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study with emphasis on differential diagnosis. Am J Surg Pathol 2004;28:453-63.
84. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch 2001;435:181-91.
85. Soslow RA, Rouse RV, Hendrickson MR, et al. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol 1996;15:257-65.
86. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 2003;27:1434-41.
87. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 1989;65:939-47.
88. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-5.
89. McCluggage WG. Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90.